Ireland's Mallinckrodt has been on a major growth spurt since its spinoff last spring from medical device maker Covidien–and it made another big move Monday in its bid to become a major specialty pharma company.
written on 07.04.2014
Mallinckrodt bets $5.6B on Questcor and its controversial Acthar drug
